In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

BioMimetic nets $16.8mm in combined financing

Executive Summary

BioMimetic Therapeutics (drug-device combo products for orthopedic indications) has completed an oversubscribed rights offering of 2mm shares at $8.50 (a 9% discount) to existing stockholders. In addition the company sold current backer Novo AS another 343k at the same price in a private placement. (Novo AS had been a standby purchaser in the rights offering but did not participate due to the oversubscription.) Total net proceeds from both transactions was $16.8mm.
Deal Industry
  • Pharmaceuticals
  • Medical Devices
    • Biomaterials
  • Biotechnology
    • Large Molecule
Deal Status
  • Final
Deal Type
  • Financing
    • Other
    • Private Placement

Related Companies